Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aggregon Oncoquest
- Development stage
- Phase 1
- Lead developer
- R2T BIOPHARMA
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
**Aggregon Oncoquest** is a personalized autologous therapeutic cancer vaccine developed using XEME Biopharma's Aggregon multilamellar liposome technology. Each patient-specific product incorporates tumor-cell lysate and/or tumor-specific neoantigens derived from the patient's own cancer together with recombinant human interleukin-2, with the aim of promoting antigen presentation and expanding tumor-reactive T-cell responses. Clinical variants include Oncoquest-CLL for treatment-naive chronic lymphocytic leukemia and Oncoquest-L for previously untreated, asymptomatic, non-bulky stage III or IV follicular lymphoma; an ovarian-cancer program has also been proposed.
- Other names
- Oncoquest
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Aggregon Oncoquest.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aggregon Oncoquest.